Terug
Dagbereik
€ 14,00
€ 14,00
52-Weeksbereik
€ 14,00
€ 14,00
Volume
100
50D / 200D Gem.
€ 14,00
/
€ 14,00
Vorige Slotkoers
€ 14,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,1 | 0,3 |
| P/B | 0,0 | 2,9 |
| ROE % | 12,5 | 3,7 |
| Net Margin % | 7,9 | 3,8 |
| Rev Growth 5Y % | 6,2 | 10,0 |
| D/E | 0,1 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 0,00
€ 0,00 – € 0,00
|
130 B | 0 |
| FY2029 |
€ 0,00
€ 0,00 – € 0,00
|
130 B | 0 |
| FY2028 |
€ 145,96
€ 143,52 – € 150,74
|
120 B | 1 |
Belangrijkste Punten
Revenue grew 6,19% annually over 5 years — modest growth
ROE of 12,53% — decent returns on equity
Debt/Equity of 0,11 — conservative balance sheet
Generating 7,52B in free cash flow
P/E of 0,12 — trading at a low valuation
Cash machine — converts 91,41% of earnings into free cash flow
Groei
Revenue Growth (5Y)
6,19%
Revenue (1Y)8,60%
Earnings (1Y)9,72%
FCF Growth (3Y)13,72%
Kwaliteit
Return on Equity
12,53%
ROIC11,77%
Net Margin7,93%
Op. Margin11,17%
Veiligheid
Debt / Equity
0,11
Current Ratio2,64
Interest Coverage1449,13
Waardering
P/E Ratio
0,12
P/B Ratio0,01
EV/EBITDA-1,24
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8,60% | Revenue Growth (3Y) | 6,53% |
| Earnings Growth (1Y) | 9,72% | Earnings Growth (3Y) | 0,71% |
| Revenue Growth (5Y) | 6,19% | Earnings Growth (5Y) | 8,27% |
| Profitability | |||
| Revenue (TTM) | 103,75B | Net Income (TTM) | 8,23B |
| ROE | 12,53% | ROA | 8,22% |
| Gross Margin | 30,18% | Operating Margin | 11,17% |
| Net Margin | 7,93% | Free Cash Flow (TTM) | 7,52B |
| ROIC | 11,77% | FCF Growth (3Y) | 13,72% |
| Safety | |||
| Debt / Equity | 0,11 | Current Ratio | 2,64 |
| Interest Coverage | 1449,13 | Dividend Yield | 0,02% |
| Valuation | |||
| P/E Ratio | 0,12 | P/B Ratio | 0,01 |
| P/S Ratio | 0,01 | PEG Ratio | 2,79 |
| EV/EBITDA | -1,24 | Dividend Yield | 0,02% |
| Market Cap | 997,73M | Enterprise Value | -14,39B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 103,75B | 95,54B | 91,42B | 86,95B | 81,61B |
| Net Income | 8,23B | 7,50B | 8,11B | 7,20B | 5,99B |
| EPS (Diluted) | 114,87 | 103,50 | 109,30 | 96,21 | 80,03 |
| Gross Profit | 31,32B | 29,25B | 28,45B | 25,54B | 25,93B |
| Operating Income | 11,59B | 10,44B | 11,40B | 9,34B | 9,89B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 100,14B | 95,83B | 97,48B | 96,11B | 94,23B |
| Total Liabilities | 33,43B | 31,17B | 33,51B | 29,95B | 31,46B |
| Shareholders' Equity | 66,71B | 64,66B | 63,97B | 66,15B | 62,76B |
| Total Debt | 7,19B | 3,60B | 6,19B | 3,10B | 4,70B |
| Cash & Equivalents | 22,57B | 13,19B | 17,61B | 18,72B | 14,35B |
| Current Assets | 69,96B | 61,23B | 62,66B | 59,90B | 58,72B |
| Current Liabilities | 26,49B | 26,10B | 27,31B | 25,72B | 25,60B |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026